There are reams of data showing the superior performance of the stock market over many generations.
These data show the superior potential of PD-L silenced DCs in the priming and expansion of MiHA-specific CD8+ T cell responses from the naive repertoire.
These data show the superior potency of PD-L silenced DCs in the priming and expansion of MiHA-specific CD8+ T cells from MiHA-negative donors.
One participant was excluded this way for the analysis with the data for number-sensitive areas extracted from the superior parietal area, 3 participants for the analysis with the data from the middle occipital area, and 2 participants for the analysis with the data from pre-SMA.
The SEM analyses were performed 3 times, with the data for number-sensitive areas extracted from the superior parietal, the middle occipital, and the medial frontal areas found in the conjunction analysis of Experiment 1.
Lastly, with real data from the Drosophila gene Dscam, we demonstrate the superior time complexity of using a factorized splice graph-based method.
A phase II study of docetaxel previously performed in our centre on patients with similar characteristics to those enrolled in the everolimus trial revealed overall response rate of 16.5%, DCR of 57% and median TTP of 2.5 months (Lee et al, 2008), which appear superior to data from the present phase II trial.
We hypothesised that in patients with platinum-sensitive ovarian cancer treated with CP, leukopenia and sensory neuropathy would be associated with superior PFS and used data from the CALYPSO trial to test this hypothesis.
The following research questions were explored: (1) Does exploratory factor analysis (FA) of the Sudanese general population data generate factors/dimensions that are similar to those of the WHO 4- and 6-domain models; (2) Does the model generated from the Sudanese general population provide a superior fit to the data from the psychiatric patients and their family caregivers, than the WHO models?
In the previously reported 12-month analysis of data from the BELA trial, bosutinib did not demonstrate a superior rate of CCyR versus imatinib (primary endpoint).
